- Adult patients (at least 18 years old) with confirmed acromegaly who have been on a stable dose of SSA monotherapy, or combination therapy with sub-optimal dose of pegvisomant for at least 6 months and whose IGF-I levels are persistently but modestly (1.0 ULN< [IGF1 serum level] > 1.3 ULN) elevated will be included.